Profile data is unavailable for this security.
About the company
SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
- Revenue in JPY (TTM)3.07bn
- Net income in JPY-4.02bn
- Incorporated2005
- Employees109.00
- LocationSymBio Pharmaceuticals LtdToranomon 30 Mori Bldg.3-2-2, ToranomonMINATO-KU 105-0001JapanJPN
- Phone+81 354721125
- Fax+81 354723054
- Websitehttps://www.symbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delta-Fly Pharma Inc | 0.00 | -1.65bn | 6.11bn | 13.00 | -- | 7.62 | -- | -- | -214.95 | -214.95 | 0.00 | 89.00 | 0.00 | -- | -- | 0.00 | -204.19 | -67.70 | -226.67 | -72.02 | -- | -- | -- | -877.69 | -- | -406.70 | 0.00 | -- | -- | -- | -7.57 | -- | -9.04 | -- |
| NIPPON CHEMIPHAR CO., LTD. | 31.54bn | -255.00m | 6.38bn | 887.00 | -- | 0.2912 | 5.66 | 0.2023 | -70.67 | -70.67 | 8,739.80 | 5,141.74 | 0.613 | 2.04 | 2.95 | 35,554,680.00 | -0.4976 | 0.7482 | -0.6958 | 1.08 | 26.07 | 30.99 | -0.8117 | 1.13 | 1.52 | -0.7018 | 0.5041 | 50.73 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| COSMO BIO COMPANY, LIMITED | 9.87bn | 367.00m | 7.05bn | 155.00 | 18.54 | 0.7611 | 13.54 | 0.7143 | 62.89 | 62.89 | 1,691.08 | 1,531.97 | 0.8932 | 5.95 | 3.96 | 63,690,320.00 | 3.49 | 5.62 | 4.06 | 6.72 | 32.98 | 37.40 | 3.91 | 6.23 | 6.67 | -- | 0.0021 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
| Wakamoto Pharmaceutical Co Ltd | 7.93bn | 190.01m | 8.29bn | 274.00 | 43.47 | 0.6914 | 13.63 | 1.05 | 5.47 | 5.47 | 228.52 | 344.22 | 0.5106 | 2.00 | 3.29 | 28,945,390.00 | 1.22 | -2.28 | 1.39 | -2.64 | 47.52 | 51.00 | 2.40 | -3.97 | 3.48 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| K Pharma Inc | 0.00 | -680.95m | 8.47bn | 15.00 | -- | 3.16 | -- | -- | -58.58 | -58.58 | 0.00 | 230.79 | 0.00 | 0.00 | -- | 0.00 | -27.16 | -- | -29.66 | -- | -- | -- | -- | -- | 34.85 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 9.25bn | 159.00 | -- | 1.80 | -- | -- | -- | -- | -- | 1,003.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.82 | -- | 0.2942 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| Perseus Proteomics Inc | 96.49m | -901.50m | 9.46bn | 25.00 | -- | 4.79 | -- | 98.08 | -74.89 | -74.89 | 8.00 | 134.05 | 0.0443 | 3.21 | 11.84 | 3,859,520.00 | -41.36 | -41.34 | -43.27 | -43.43 | 87.73 | 91.72 | -934.32 | -891.26 | 19.91 | -- | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Solasia Pharma KK | 159.00m | -1.29bn | 9.82bn | 24.00 | -- | 4.57 | -- | 61.75 | -7.36 | -7.36 | 0.9065 | 9.85 | 0.0639 | 0.8549 | 0.5256 | 6,625,000.00 | -51.68 | -48.57 | -59.50 | -58.83 | 31.45 | 71.01 | -808.81 | -300.89 | 3.42 | -61.24 | 0.0219 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| ReproCell Inc | 2.49bn | -178.74m | 10.00bn | 96.00 | -- | 1.13 | -- | 4.02 | -2.03 | -2.03 | 28.72 | 93.57 | 0.2826 | 4.76 | 6.63 | 25,940,160.00 | -2.03 | -7.35 | -2.20 | -8.00 | 48.99 | 39.83 | -7.18 | -27.16 | 9.99 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| RaQualia Pharma Inc | 2.30bn | -673.00m | 10.56bn | 67.00 | -- | 1.87 | -- | 4.59 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Symbio Pharmaceuticals Ltd | 3.07bn | -4.02bn | 11.02bn | 109.00 | -- | 2.13 | -- | 3.59 | -92.13 | -92.13 | 70.03 | 112.55 | 0.4225 | 2.97 | 4.47 | 28,137,370.00 | -55.36 | -19.18 | -62.58 | -23.62 | 77.57 | 65.84 | -131.05 | -24.32 | 6.51 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Ohki Healthcare Holdings Co Ltd | 254.49bn | 1.28bn | 11.72bn | 632.00 | 8.93 | 0.3805 | 7.74 | 0.0461 | 93.26 | 93.26 | 18,553.59 | 2,189.15 | 1.82 | 9.59 | 3.36 | 402,672,500.00 | 0.875 | 1.85 | 3.76 | 8.42 | 4.99 | 6.16 | 0.481 | 0.7178 | 0.8641 | -- | 0.2547 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
Data as of Nov 13 2024. Currency figures normalised to SymBio Pharmaceuticals Ltd's reporting currency: Japanese Yen JPY
0.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Simplex Asset Management Co., Ltd.as of 03 Oct 2024 | 246.90k | 0.54% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 60.60k | 0.13% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 11.50k | 0.03% |
| DFA Australia Ltd.as of 31 May 2023 | 2.27k | 0.01% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
